Sat, Dec 27, 2014, 4:56 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Achillion Pharmaceuticals, Inc. (ACHN) Message Board

  • nusaiba nusaiba Oct 1, 2013 12:49 PM Flag

    Leerink Swann initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $10.

    Leerink Swann initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $10.

    Leerink analyst says, "We believe that ACHN's portfolio could be attractive to potential partners or acquirers. We note that assets in the HCV protease inhibitor and NS5a inhibitor classes available for partnering are relatively scarce, and historical deals have commanded good premiums...We recognize that ACHN's compounds are still early, and safety or efficacy issues could still arise. However, we believe the risks are mitigated to some extent by a portfolio of three distinct compounds, and we see the upside worth taking the risk."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACHN
12.82-0.2400(-1.84%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.